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вано повышенное содержание нейротрофинов ФРН и ФРГМ в плазме крови у больных с 
поражением  двигательного неврона у больных спинальной мышечной атрофией и сниже-
ние  ФРГМ у больных с поражением мышечной системы у больных с мышечной дистро-
фией Дюшенна. Полученные данные свидетельствуют об особенностях  нейротрофиче-
ской регуляции у больных наследственными мышечными атрофиями и мышечными дис-
трофиями, которые необходимо учитывать при проведении симптоматического лечения, 
направленного на стимулирование репаративных  процессов в нервной ткани. Больным с 
нейрит-ослабленным действием плазмы крови рекомендовано проводить терапию нейро-
протективными препаратами, у больных с нейрит-ингибирующим эффектом на нейриты в 
органнотипической культуре нервной ткани рекомендовано проводить подбор препарата в 
условиях in vitro индивидуально путем фармакологического анализа.   
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Introduction. Hemophilia A is an X‐linked genetic hemorrhagic disorder resulting from 
a deficiency of blood coagulation factor VIII (FVIII). The main treatment for hemophilia is a 
replacement therapy, when purified concentrates of plasma-derived FVIII (pdFVIII) or 
recombinant FVIII (rFVIII) are infused [1]. The development of inhibitors, which are 
alloantibodies that inhibit the procoagulant function of FVIII, is currently the most challenging 
complication of treatment in persons with hemophilia A. Inhibitors significantly increase the 
costs of care, intensify the financial and psychosocial stressors on patients and their families, and 
have a negative effect on disease morbidity and mortality by making bleeding episodes more 
difficult to treat [2]. 
Among hemophilia A patients with severe FVIII deficiency, about 30 % of them respond 
to infusion therapy immunologically, producing anti-FVIII antibodies. An important issue 
related to the choice of pd- versus rFVIII is that of the comparative efficacy of the two sources of 
replacement therapy in achieving immune tolerance, the best method to eradicate inhibitors 
through the long-term treatment of patients with replacement therapy with coagulation factors. 
Not all antibodies to FVIII act as inhibitors. Non-neutralizing antibodies directed against 
coagulation factors may be seen in individuals with hemophilia and in the general population [3]. 
Unfortunately, no randomized clinical trials are currently available in Ukraine to provide definite 
evidence on whether or not a difference in immunogenicity exists between plasma-derived and 
recombinant FVIII concentrates. 
Conventionally, inhibitor titers are measured with the Bethesda inhibitor assay (BIA). 
Dilutions of the patient’s plasma are incubated with normal pooled plasma for 2 hours at 37°C, 
and the residual FVIII is measured. One Bethesda unit (BU) is defined as the quantity of 
inhibitor that neutralizes 50% of the FVIII in normal plasma after 2 hours’ incubation at 37 °C 
[4].  In 1995, the BIA was modified to stabilize the protein and pH during incubation. As a 
result, the Nijmegen-Bethesda assay was adopted by the International Society on Thrombosis 
and Hemostasis. Titers of 0.6 BU/mL or greater are considered to be inhibitor positive [5]. 
However, there are several limitations to such laboratory measurements of inhibitors, including a 
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limited sensitivity for low titer inhibitors [<0.4 BU/mL]. BIA detects only inhibitors that reduce 
FVIII activity (inhibitory), while immunochemical assays can detect both inhibitory and non-
inhibitory antibodies and may have improved detection capacity for low-titer inhibitors, but they 
need further clinical validation to support their widespread use [6]. Thus, due to high incidence 
of the development of antibodies to clotting factors (both neutralizing and non-neutralizing) in 
patients receiving exogenous factor concentrates, and higher sensitivity of immunological tests, 
there is an urgent need for affordable immunological diagnostic kits for routine screening of 
large populations of patients with bleeding disorders. The purpose of the present study was to 
compare sensitivity of distinct immunochemical assays in detecting antibodies to FVIII in 
patients with hemophilia A, using pdFVIII or rFVIII as target antigens. 
Materials and methods. The study was performed on citrated plasma samples obtained 
from healthy persons (n = 3), which were used as controls, and individuals with clinically 
confirmed hemophilia A (n = 8), which obtained FVIII concentrates’ infusions as a replacement 
therapy. The anti-FVIII inhibitor assay was performed as described by Kasper et al. [4]. 
According to BIA results, patients were divided into two groups: four inhibitor-negative patients 
(< 0.6 BU/mL) and four inhibitor-positive samples (> 0.6 BU/mL), which had 1.0, 1.78, 2.6, and 
4.36 BU/mL. Human studies were approved by the Institutional Review Boards at the State 
Institution “Institute of Blood Pathology and Transfusion Medicine of AMSU”. Donors’ 
informed consents were obtained in accordance with the Declaration of Helsinki.  
Antibodies to FVIII in plasma samples were detected by enzyme-linked immunosorbent 
analysis (ELISA) and immunoblotting. For evaluation of anti-FVIII antibodies, highly purified 
albumin-free B domain-free rFVIII (ReFacto® AF, Wyeth Farma S.A., Madrid, Spain) or 
pdFVIII (Bioclot A, Biopharma, Ukraine) were used as target antigens (2 µg per well). After 
coating and blocking procedures, plates were incubated with the tested human plasmas in various 
dilutions, followed by washing steps, incubation with the appropriate secondary sheep anti-
human HRP-conjugated IgG, and incubation with the chromogenic substrate (3,3′,5,5′-
tetramethylbenzidine, TMB). Finally, substrate reaction was stopped by adding 50 μL of 2.5 N 
H2SO4 per well. The absorbances of colored reaction products were measured at 450 nm 
(primary test filter) and 620 nm (reference filter) in a microELISA reader. Optical density values 
at 1:1,000 dilution were taken for comparison analysis. All samples were tested at least in 
duplicate. The final results were expressed as the mean A(450-620)nm. 
In order to detect anti-FVIII antibodies by immunoblotting, two target FVIII-related 
antigens (pdFVIII or rFVIII, 5 µg per track) were electrophoretically separated and transferred 
onto nitrocellulose membranes by electroblot in 0.025 M tris-HCl solution, containing 0.195 M 
glycine and 25 % (v/v) methanol. After blocking in 5 % skim milk solution, membranes were 
stripped and probed with plasmas of healthy donors or individuals with hemophilia A (1:1,000 
diluted) overnight at 4 
o
C. For immunoblot analysis of FVIII-related proteins in several batches 
of pdFVIII concentrates, the membrane was incubated with rabbit anti-FVIII antibodies 
generated against rFVIII B domain-free rFVIII, or moroctocog alpha [7]. After washing, bound 
antibodies were identified by incubating membranes with the appropriate secondary HRP-
conjugated antibodies. Non-specifically bound antibodies were removed by five-times washing. 
FVIII specific immunostaining was detected with the use of enhanced chemiluminescence 
method. The membranes were treated with luminol (0.25 M luminol diluted in DMSO, 0.09 
coumaric acid diluted in DMSO, 0.1 M tris pH 8.5, and 0.0035% H2O2) for 1 min and exposed 
on X-ray film (Konica Minolta, Japan). Signals were visualized, digitized, and analyzed using 
TL120 software (TotalLab Ltd., USA). Molecular weights were determined using standard 
prestained molecular weight protein ladder. The results were expressed as units of density × band 
area and referred to as arbitrary units (a.u.).  
Statistical differences between mean values of immunostaining intensities were evaluated 
by one-way ANOVA followed by Tuckey’s post-hoc test using OriginPro 8.6 version 
(OriginLab Corp., USA). The confidence interval (P) less than 0.05 was considered statistically 
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significant. The quantitative results of ELISA and immunoblot analysis were illustrated as ‘box-
and-whiskers’ plots. 
Results and discussion. Immunoblotting of plasma-derived concentrate of natural full-
length FVIII molecules (Fig. 1) revealed two distinct immunoreactive polypeptides: major 
polypeptide of ~ 250 kDa and minor band of ~ 315 kDa. The identical bands were revealed by 
immunoblotting with the use of plasma samples as a source of primary antibodies and a pdFVIII 
concentrate as a target antigen (Fig. 2). Notably, one of three healthy donor samples was found 
to contain antibodies that bind to FVIII-related polypeptides. This observation can be explained 
by the fact that anti-FVIII antibodies may be present in 20 % of healthy individuals with normal 
levels of FVIII in plasma, as shown by Algiman et al. [8] and recently confirmed by Miller [9]. 
The biological significance of natural autoantibodies is not yet understood, however, there is 
evidence that these antibodies may have immunoregulatory functions, playing a role in protein 
and cell catabolism [10].  Wootla et al. [11] have reported that autoimmune FVIII inhibitors may 
neutralize the procoagulant activity of endogenous FVIII by proteolysis, thus acting as natural 
regulators of blood coagulation cascade. 
However, immunostaining of the FVIII-related antigens appeared to be significantly 
stronger in the samples of hemophiliac individuals (Fig. 2). Compared to healthy subjects, the 
densities of 315 kDa band in hemophilia patients without clinically detectable inhibitor (< 0.6 
BU/mL) and especially in those having clinically significant inhibitor (> 0.6 BU/mL) were 5,14- 
and 7.23-fold higher, respectively. Non-significant increase in immunostaining (1,81-fold, P > 
0.05) was observed for 250 kDa band in plasma of patients without inhibitor compared to 
healthy individuals, while plasmas of inhibitor patients produced significantly stronger signal 
than control healthy individuals (4,57-fold, P < 0.01). 
 
Fig. 1. – Immunoblot of various batches of pdFVIII (Bioclot A, Biopharma): primary rabbit 
antibodies to FVIII, secondary goat anti-rabbit IgG-HRP conjugates (1:80,000 diluted)  
(Sigma Aldrich, USA) 
 
Fig. 2. – Immunoblot of anti-FVIII antibodies in healthy donor plasma and plasma of 
patients with hemophilia A with the use of pdFVIII (Bioclot A, Biopharma) as a target antigen. 
“Box-and-whiskers” represent results of densitometry analysis. * - P < 0.05 vs. Control, # - P < 0.01 
vs. Control 
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Results of immunoblot assay demonstrate significant difference in binding capacities of 
circulating anti-FVIII antibodies to the target antigens of different origin. Unlike pdFVIII target 
antigen, B domain-free rFVIII (moroctocog alpha) was recognized by plasma IgG to much lesser 
extent (Fig. 3). Detectable signal levels were produced only in plasmas of patients with clinically 
significant inhibitor. Weak level of immunostaining in the case of rFVIII molecules could reflect 
the lesser amount of epitopes due to deleted B-domain, or changes in their conformation after 
denaturing gel-electorphoresis, as compared to pdFVIII. Therefore, the main conclusion which 
may be made on the basis of the described results is that immunoblotting with the native pdFVIII 
molecules as target antigen was capable to discriminate between normal plasmas and plasmas 
containing a FVIII-antibodies, including those unrecognized by the BIA (< 0.6 BU/mL). 
 
 
 
Fig. 3. – Immunoblotting of FVIII antibodies in donor plasma and plasma of patients with 
hemophilia A with the use of rFVIII (B domain-free rFVIII, or moroctocog alpha, ReFacto® AF, 
Wyeth Farma S.A.) as a target antigen 
 
In contrast, when rFVIII was used as an coating antigen on the ELISA plates, the mean 
level of anti-FVIII IgG did not differ significantly between healthy donor plasmas and plasmas 
of patients without clinically significant inhibitor (< 0.6 BU/mL)  (Fig. 4). However, pdFVIII 
gave the highest sensitivities for anti-FVIII antibody detection in plasmas without detectable 
BIA titers (at least 3-fold, P < 0.05), but not for plasma samples with > 0.6 BU/mL values, 
providing equal sensitivity with rFVIII in that BU titer range. Thus, our results obviously 
demonstrate that characteristics of FVIII molecules used as target antigens might affect the 
results of immunochemical detection. 
 
 
Fig. 4. – ELISA detection of anti-FVIII antibody levels in donor plasma and plasma of 
patients with hemophilia A with the use of pdFVIII or rFVIII as target antigens (plasma dilution 
1:1,000): A – individual data, B – mean data. * - P < 0.05 between corresponding “pdFVIII” and 
“rFVIII” mean values; # - P < 0.05 between “> 0.6 rFVIII” and other “rFVIII” mean values 
 
FVIII functions as a cofactor to factor IXa in the tenase complex, and a deficiency of 
factor VIII thus reduces the generation of thrombin on the surface of activated platelets. FVIII is 
synthesized as a 330-kDa precursor protein having an A1-A2-B-A3-C1-C2 domain structure 
with an activation peptide between the B and A3 domains. After proteolytic processing, FVIII 
associates with von Willebrand factor (VWF) in heterodimers of a heavy (A1-A2) and a light 
Ре
по
зи
то
ри
й 
 
 
 
По
ле
сГ
У
107 
 
(A3-C1-C2) chain associated by a metal ion interaction [12]. Most acquired FVIII inhibitors bind 
to the A2, A3 or C2 domains. Anti-C2 antibodies disrupt the binding of FVIII to phospholipid 
and VWF, while antibodies to A2 and A3 interfere with FVIII binding to factor X and factor IXa 
[13]. Higher IgG binding capacity to the native pdFVIII-related proteins compared to rFVIII 
molecules, found by blotting assay, could be a result of dissociation of FVIII molecules from 
VWF due to protein denaturation during gel-electrophoresis. B domain-free rFVIII (moroctocog 
alpha) is a genetically engineered antihemophilic factor with an approximate molecular weight 
of 170 kDa and consisting of two chains, 90 and 80 kDa [14]. Possibly, lack of B domain, 
bearing additional epitopes, in rFVIII molecule used as a target antigen may as well cause its 
decreased performance in both immunoblotting and ELISA. These results are in line with earlier 
observation of Butenas et al. [15] who demonstrated B domain to bind a significant fraction of 
anti-FVIII antibodies.  
Immunochemical assays are much more sensitive than functional assays in detection of 
anti-FVIII antibodies. Because they measure both inhibitory and non-inhibitory antibodies, they 
are not equivalent to and cannot be substituted for functional inhibitor assays. They may be used 
to screen specimens for those requiring inhibitor assays or to confirm the presence of specific 
antibodies. The present pilot study is the first report providing a comprehensive description of 
immunoblot assay based on the enhanced chemiluminiscence technique for anti-FVIII antibody 
polypeptide profile investigations. The apparent consistency of the findings made by 
immunoblot analysis and results scored in plasmas by BIA supports the legitimacy and potential 
usefulness of the described immunochemical method as a supplementary approach to BIA.  
Conclusions. We showed here that, unlike ELISA, immunoblot analysis using pdFVIII 
as a source of antigen and optimized by chemiluminescence technology is able to efficiently 
discriminate between normal plasmas and hemophiliac patients’ plasmas, containing even low 
titers of FVIII antibodies, undetectable by BIA (< 0.6 BU/mL). Summarizing, we highlight that 
the use of a similar immunoblot technique for detection and screening for anti(auto)-FVIII 
antibodies could facilitate future researches of coagulation inhibitors development, and 
potentially serve as highly sensitive and informative diagnostic and/or prognostic tool. 
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Протеасомы, мультипротеолитические субкомплексы, регулируют клеточные про-
цессы, образуя биологически активные пептиды и гидролизуя рецепторы, факторы роста, 
компоненты сигнальных путей, транскрипционные факторы и другие белки. Кроме того, 
протеасомы контролируют качество белков и устраняют те из них, у которых повреждена 
теритичеая структура. Многочисленные функции протеасом обусловлены множественно-
стью их форм, различающихся структурой и, следовательно, спецификой гидролиза бел-
ков. Возникновение и развитие различного рода патологий во многом связано с изменени-
ем клеточного пула протеасом. Рост злокачественных опухолей сопровождается возраста-
нием химотрипсинподобной (ХТП) активности протеасом и увеличением экспрессии 26S-
протеасом, распознающих и гидролизующих убиквитинированные полноразмерные бел-
ки. Причем это справедливо как для экспериментальных опухолей грызунов, так и для 
злокачественных новообразований человека. Более того, регрессия опухолей у грызунов 
сопровождается резким падением указанных параметров протеасом. Таким образом, про-
теасомы представляют собой перспективную модель для противоопухолевых воздей-
ствий.   
С 2003 года в клинической практике используется первое противоопухолевое со-
единение, бортезомиб, являющееся конкурентным обратимым ингибитором ХТП-
активности протеасом. Бортезомиб применяется внутривенно, главным образом, для лече-
ния гематологических онкологических заболеваний, более чувствительных к нему по 
сравнению с солидными опухолями. Вместе с тем, это соединение вызывает серьезные 
побочные эффекты, к числу которых относятся периферическая нейропатия, тромбоцито-
пения, нарушение функций желудочно-кишечного тракта, отклонения в сердечной дея-
тельности, слабость. С целью снижения побочных эффектов и улучшения противоопухо-
левой эффективности синтезированы новые ингибиторы протеасом. Некоторые из них – 
карфилзомиб (необратимый ингибитор ХТП-активности протеасом) и иксазомиб (препа-
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